As a child of Apollo now watching current day MSM cover today’s efforts the differences are startling.
Factual scientific coverage from professionals has been replaced with superficial DRAMA from deep voiced slow talking ghouls who want an emergency.
Bring back scientists and professionals.👇

Oryon shines out of stealth with $21M to fight Parkinson's disease When Ron Cohen, M.D., CEO of Oryon Cell Therapies, recently dug into the company’s Parkinson’s disease data, he told Fierce Biotech it “sang” to him. | When Ron Cohen, M.D., CEO of Oryon Cell Therapie...

Oryon shines out of stealth with $21M to fight Parkinson's disease

www.fiercebiotech.com/biotech/oryo...

Not sure what this says about me that I noticed it, but last night the number of papers on the NIH's Pubmed database with the key word "Parkinson's" ticked over the 200,000 milestone:

Researching Parkinson's outside the Golden Triangle The Dundee lab that punches above its weight

open.substack.com/pub/rorycell... Had a great day in Dundee meeting scientists doing world leading Parkinson’s research far from the London/Oxbridge triangle

5 Investigational Therapies That Could Change the Parkinson’s Landscape From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s di...

Nice read on "5 investigational therapies that could change the #Parkinsons landscape"
www.biospace.com/drug-develop...

Check out my newest Substack column on bending the cause of Parkinson's disease through improved sleep.
Spoiler alert: your brain's 'glymphatic system' is more than just plumbing.
michaelokun.substack.com/p/can-we-ben...

Our research highlights for 2025 are here, which proved to be one of our most exciting years yet for Parkinson’s research! Find out more about these updates and learn what else is in store for 2026 in our annual research recap: buff.ly/RnGgUqM

Dairy fat and dementia, do you know what the data shows? Spoiler alert: HIGH fat cheese and cream associated w/ lower dementia risk. A large long-term study examining how different types of dairy related to dementia risk. There were more than two decades of follow-up. @parkinsondotorg.bsky.social

"The results of this study have important implications, given the emphasis on patient-centered care & on patient-focused drug development & evaluation"

Read more about what people with #Parkinsons say matters most for quality of life
movementdisorders.onlinelibrary.wiley.com/doi/10.1002/...

Movers and Shakers - what a year! For our final episode of 2025 Movers and Shakers looks back on a momentous year, choosing our favourite episodes and stand-out moments.

open.substack.com/pub/rorycell... In our last episode of 2025 Movers and Shakers looks back on a momentous year for our podcast about living with Parkinson’s

What is the burden in the US of Parkinson's, Alzheimer's and other diseases? Spoiler alert: there are surges beyond the pure numbers and we need to raise awareness for the increases in both disability and burden. Parkinson disease has shown the largest growth in burden on society.
cutt.ly/xtyUtS0D

Casting announced for But When We Dance Laura Linney and Rhys Ifans star in a touching story about two people with lots in common - a great sense of humour, a love of dance, and Parkinson’s

www.bbc.co.uk/mediacentre/... This movie about Parkinson’s which is being filmed right now will be one of the highlights of 2026

II’m looking forward to it too

Do NOT swim alone if you have Parkinson's. Do we do enough to warn people about drowning? Did you know if you have Parkinson's, you can 'freeze' when swimming, and it could be an early warning sign for later Parkinson’s freezing of gait.

A $1 billion question about Parkinson’s Two events ponder whether a large injection of cash could spark a breakthrough

open.substack.com/pub/rorycell... My latest from the frontline of the battle to cure Parkinson’s - could one huge donation bring the breakthrough that has been so long in coming?

'My sin was having Parkinson's': Presenter left stranded Mark Mardell was left feeling 'humiliated' after he was told he could not board a flight.

Airline strands ex-BBC editor, citing Parkinson's www.bbc.com/news/article... Don’t travel with Turkish Airlines- they discriminate against people with Parkinson’s

Huge news - Parliament is going to debate the #parkypetition on November 17th

Parkinson's - the diagnosis crisis UK's neurologist shortage continues to bite, says biggest PD audit

open.substack.com/pub/rorycell... Biggest ever audit of Parkinson’s in the UK says there’s a diagnosis crisis with a shortage of neurologists leaving thousands waiting up to 5 years to see a specialist

Acetyl-DL-leucine (Tanganil™) in three patients with advanced multiple system atrophy - BMC Neurology Background Multiple system atrophy (MSA) is a rare, rapidly progressive alpha-synucleinopathy characterized by autonomic dysfunction, parkinsonism and marked cerebellar ataxia, with very limited treatment options. N-acetyl-DL-leucine (ADLL) (Tanganil™), a racemic derivative of leucine is usually well tolerated and has shown promise in improving cerebellar symptoms and reducing REM sleep behavior disorder (RBD), a common non-motor dream-sleep disorder feature of alpha-synucleinopathy. Given this dual potential, we treated three patients with advanced-stage MSA under compassionate use rules. Case presentations Three patients with advanced-stage MSA and severe cerebellar symptoms—two of whom also had moderate RBD—were treated with ADLL (TanganilTM), titrated to 5g/day over 10 days. While both patients with RBD reported self-assessed decrease of RBD symptoms within 2–3 weeks on the full dosage (approximately four weeks after treatment initiation), all three patients had major worsening of gait and balance during the same period, leading to sudden falls and overall health decline. These adverse events prompted early discontinuation of therapy. Gait improved within two weeks after discontinuation of therapy in two patients. In parallel, the RBD phenotype reoccurred. In the third, who had very advanced MSA and concurrent infections, gait only slowly improved over time and it remains unclear whether his worsening of truncal ataxia was attributable to ADLL (TanganilTM), or whether it was related to his concurrent infections with slow recovery. Conclusions While ADLL improved RBD, it was poorly tolerated in these three patients with advanced-stage MSA of predominantly cerebellar type. Further studies are needed to evaluate its safety and efficacy in different, preferably early, stages of MSA.

Acetyl-DL-leucine (Tanganil™) administration in 3 people with advanced multiple system atrophy led to ⬇ REM sleep behavior disorder symptoms within 2–3 weeks (~4 weeks after treatment initiation), but all 3 patients had major worsening of gait & balance
bmcneurol.biomedcentral.com/articles/10....

Very excited about this - @cureparkinsons.org.uk has a funding call for your best combination therapy ideas for disease modification in #Parkinsons
👉Preclinical or clinical projects
👉Must have a solid, well-backed rationale
👉Expressions of interest due 24/11
DM me if you have any questions

High Cerebrospinal DOPA Decarboxylase Level Predicts Cognitive Decline in Parkinson's Disease Background DOPA decarboxylase (DDC) in cerebrospinal fluid (CSF) is an emerging Parkinson's disease (PD) biomarker, but its association with nonmotor symptoms is unclear. Objectives We aimed to de...

New research reports that high cerebrospinal fluid DOPA decarboxylase levels predict cognitive decline in #Parkinsons patients - potential biomarker?
movementdisorders.onlinelibrary.wiley.com/doi/10.1002/...

Results of a PhotoPharmics trial (NCT02175472) assessing daily light therapy (with a circadian effective targeted spectrum of light) reports the treatment was safe in 92 people with #Parkinsons & showed improvement in both motor & non-motor MDS-UPDRS
www.neurotherapeuticsjournal.org/article/S187...

What medicines do people with Parkinson's disease want? - Kevin McFarthing, Tiago Fleming Outeiro, Maria Carmo Bastos, 2025 Parkinson's disease (PD) is a heterogeneous condition that presents variable clinical, neuropathological, and biomarker features. Disease progression can a...

What medicines do people with Parkinson's want?
@touteiro.bsky.social , Carmo Bastos and I try to answer the question in @journal_PD #Parkinsons . It's #openaccess as well.

journals.sagepub.com/doi/full/10....

Shades of grey: The continuum of therapies for Parkinson's disease along the spectrum of credibility - Araceli Alonso-Canovas, Olaf M Dekkers, Bas Bloem,

journals.sagepub.com/doi/10.1177/...

S.BIOMEDICS announced encouraging one-year post-transplant results from Phase 1/2a clinical trial evaluating A9-DPC cell therapy for #Parkinsons; Favorable safety & efficacy profile of A9-DPC in 12 participants at 12 months compared to baseline
www.manilatimes.net/2025/07/21/t...

Pharmather eyes commercialization of Parkinson’s ketamine drug The FDA plans to make a decision on Aug. 9 regarding a ketamine-based product that Pharmather hopes to investigate for Parkinson's dyskinesia.

parkinsonsnewstoday.com/news/pharmat...

Interesting - more data on tanganil (acetyl-leucine) - this is a 2-year case study in a patient with #Parkinsons & REM sleep behaviour disorder (RBD); Treatment helps with RBD symptoms; PD analysis is in the supplemental data file
link.springer.com/article/10.1...

Gaining Ground: The Pursuit of Improving and Introducing New Parkinson’s Medications

A nice summary of my recent webinar with the Parkinson's Foundation on the Parkinson's drug development pipeline @ParkinsonDotOrg
www.parkinson.org/blog/awarene...

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s...

The press summary associated with this research: www.globenewswire.com/news-release...

Exploratory digital outcome measures of motor sign progression in #Parkinsons collected by Roche in their Phase 2 PASADENA study of the anti-alpha-synuclein monoclonal antibody prasinezumab have been published - encouraging data for digital biomarkers
www.nature.com/articles/s41...